S&P 500 Healthcare Sector SEC Filings — February 26, 2026

27-02-2026

Western New England Bancorp, Inc. announced on February 24, 2026, that Paul Picknelly, a member of its Board of Directors, will retire effective May 14, 2026, immediately following the 2026 Annual Meeting of Stockholders. Mr. Picknelly's decision was not due to any disagreement with the company's operations, policies, or practices. No other changes or financial impacts were disclosed.

27-02-2026

On February 24, 2026, Hadar Levy, a Class I director on the Board of Directors of Lifeward Ltd., notified the company of his decision to step down from the Board, effective immediately. His departure did not result from any disagreement with the company's operations, policies, or practices. The company expressed gratitude for his distinguished service and contributions.

• ·Filing date: February 27, 2026
• ·Company address: 2 Cabot Rd., Hudson, MA 01749
• ·Trading symbol: LFWD (Nasdaq Capital Market)

27-02-2026

Cigna Group filed an 8-K on February 27, 2026 (AccNo: 0001140361-26-007049, Size: 162 KB) under Item 7.01 for Regulation FD Disclosure. No specific core event, financial metrics, transactions, or quantitative data are disclosed in the provided filing information. All details on impacts, guidance, or scheduled events remain NOT_DISCLOSED.

27-02-2026

On February 26, 2026, Jupiter Neurosciences, Inc. received Nasdaq notices for non-compliance with the Minimum Bid Price Requirement (closing bid price < $1.00 for 30 consecutive business days from January 13 to February 25, 2026) and the MVLS Requirement (market value of listed securities below $35M for the same period), both critical for continued listing on Nasdaq Capital Market. However, the Company has 180 calendar days until August 25, 2026, to regain compliance by meeting $1.00 bid for 10+ consecutive business days and $35M MVLS for 10 consecutive days, with trading continuing uninterrupted under ticker JUNS. The Company plans to monitor and may pursue options like a reverse stock split, though success is uncertain.

• ·Nasdaq may require bid price maintenance beyond 10 days, up to 20 consecutive business days.
• ·Eligibility for second 180-day compliance period requires meeting MVLS and other initial listing standards (except bid price) and notifying intent to cure, potentially via reverse stock split.
• ·Designated disclosure channels: website https://jupiterneurosciences.com, X @jupiterneuro, Instagram @Nugevia.
• ·Address: 1001 North US HWY 1, Suite 504, Jupiter, FL 33477; Phone: (561) 406-6154.

27-02-2026

Bain Capital Specialty Finance, Inc. filed an 8-K on February 27, 2026, disclosing information under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, transaction details, or guidance are provided in the filing summary. This appears to be a multi-item voluntary or mandatory earnings-related disclosure, but quantitative impacts are NOT_DISCLOSED.

27-02-2026

News Corp filed an 8-K on February 27, 2026 (AccNo: 0001564708-26-000043, size 399 KB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). Specific details of the other events or attached exhibits are NOT_DISCLOSED. No financial metrics, transactions, or performance data are mentioned.

27-02-2026

FrontView REIT, Inc. filed a Form 8-K on February 27, 2026, disclosing multiple material events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 3.03 (Material Modifications to Rights of Security Holders), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific transaction values, share counts, or financial metrics disclosed in the provided information. No positive or negative performance metrics are mentioned.

27-02-2026

Nuveen AMT-Free Municipal Value Fund filed a Form 8-K on February 27, 2026, reporting solely under Item 8.01 Other Events. No specific details regarding the nature of the other events, financial metrics, transactions, or impacts are disclosed in the provided filing information. This appears to be a single-item, voluntary disclosure with no quantitative data available.

27-02-2026

Nuveen Municipal Value Fund Inc filed a Form 8-K on February 27, 2026, under Item 8.01 Other Events. No specific details regarding the core event, transaction, financial metrics, positive or negative changes, or other quantitative data are disclosed in the filing summary provided. This appears to be a single-item voluntary or mandatory disclosure of a material event not covered by other Items, but content is limited.

27-02-2026

National CineMedia, Inc. filed an 8-K on February 27, 2026, under Item 2.02 disclosing results of operations and financial condition. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are mentioned in the provided filing information. Detailed financial impacts remain NOT_DISCLOSED.

27-02-2026

MBX Biosciences, Inc. filed an 8-K on February 27, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 5.02 departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 discloses financial statements and exhibits. No specific details, numerical values, transaction sizes, personnel names, or financial impacts are provided in the filing summary.

27-02-2026

LCI Industries filed a Form 8-K on February 27, 2026 (AccNo: 0000763744-26-000014, Size: 705 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the exhibits are disclosed in the filing summary. This appears to be a multi-item voluntary disclosure with attached exhibits.

27-02-2026

Avidity Biosciences, Inc. filed an 8-K on February 27, 2026, disclosing the termination of a material definitive agreement (Item 1.02), completion of an acquisition or disposition of assets (Item 2.01), notice of delisting or failure to satisfy listing standards (Item 3.01), material modifications to rights of security holders (Item 3.03), changes in control of the registrant (Item 5.01), departures/elections of directors/officers and compensatory arrangements (Item 5.02), and amendments to articles of incorporation or bylaws (Item 5.03). These items collectively indicate a completed significant corporate transaction involving change of control and delisting, with no financial metrics, deal values, or performance comparisons provided. Item 9.01 references financial statements and exhibits, but specifics are NOT_DISCLOSED.

27-02-2026

CIMG Inc. announced on February 27, 2026, that it received a letter from Nasdaq on February 23, 2026, stating the Nasdaq Hearings Panel will consider the company's failure to timely file its Form 10-Q for the period ended December 31, 2025, as an additional basis for potential delisting under Nasdaq Listing Rule 5250(c)(1) during the monitor period. The company is working diligently to complete and file the overdue 10-Q, with no immediate impact on the trading of its common stock under the symbol 'IMG' on The Nasdaq Capital Market. This development heightens delisting risks amid ongoing compliance issues.

• ·Company website: http://www.ccmg.tech
• ·IR contact: ir@ccmg.tech, +852 70106695

27-02-2026

Triumph Financial, Inc. (NYSE: TFIN) declared a quarterly cash dividend of $17.81 per share on its 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock, equivalent to $0.44525 per depositary share (NYSE: TFIN-PR). The dividend is payable on March 30, 2026, to holders of record at the close of business on March 15, 2026. No period-over-period comparisons or other financial metrics were provided in the announcement.

• ·Triumph is headquartered in Dallas, Texas.
• ·Company's Annual Report on Form 10-K filed with SEC on February 11, 2026.
• ·Investor Relations: lwyse@tfin.com, 214-365-6936; Media: atavackoli@tfin.com, 214-365-6930.

27-02-2026

Precipio's fiscal 2025 revenues grew 30% YoY to $24.0M from $18.5M in 2024, with Q4 2025 revenues at $6.7M, up 23% from $5.4M in Q4 2024. Adjusted EBITDA turned positive at $1.23M for full year 2025 (vs -$1.5M in 2024) and $0.95M in Q4 2025 (vs $0.40M in Q4 2024). Operating cash flow improved to $688K for 2025 from $439K in 2024, with adjusted operating cash flow at $727K excluding unusual items.

• ·Q4 2025 EBITDA (non-GAAP) of $0.9M vs $0.0M in Q4 2024.
• ·Shareholder call planned in early April 2026 following 10-K filing.
• ·Adjusted operating cash flow for Q4 2025 was $617K excluding unusual items.

27-02-2026

Disc Medicine, Inc. approved a restructuring plan on February 26, 2026, to reduce its workforce by approximately 20%, primarily in commercial and supporting functions, following an FDA complete response letter on February 13, 2026, for its bitopertin New Drug Application. The company expects $2.0 million in aggregate charges, mainly severance, to be recorded primarily in Q1 2026, with implementation completing in Q2 2026. This move aligns the workforce with near-term priorities amid the regulatory setback.

• ·Restructuring primarily affects commercial functions and certain supporting functions.
• ·FDA complete response letter dated February 13, 2026, for bitopertin NDA treating erythropoietic protoporphyria and X-linked protoporphyria.
• ·Actual costs may differ from estimates due to assumptions and potential additional expenses.

27-02-2026

Ensysce Biosciences, Inc. received a Nasdaq deficiency notice on February 25, 2026, stating non-compliance with Listing Rule 5550(a)(2) as the common stock bid price closed below $1.00 for 30 consecutive business days. The company has 180 calendar days until August 24, 2026, to regain compliance by achieving a minimum bid price of $1.00 for at least 10 consecutive business days, with no immediate impact on trading under symbol ENSC. Failure to comply could lead to delisting, impairing liquidity, capital raising, and stock value.

• ·Company intends to monitor bid price and evaluate options like reverse stock split if needed
• ·Possible second 180-day compliance period if initial period fails and other standards met
• ·Delisting appeal possible to Nasdaq hearings panel, but no assurance of success

27-02-2026

Jewett-Cameron Trading Company Ltd. held its Annual General Meeting on February 27, 2026, where shareholders approved receipt of financial statements for the fiscal year ended August 31, 2025, fixed the board at five directors, elected Charles E. Hopewell, Michelle Walker, Chad Summers, Subriana Pierce, and Ian Wendler as directors, appointed auditors, ratified directors' and officers' acts, and approved executive compensation on an advisory basis. However, several proposals faced significant opposition, including acts and deeds of directors/officers (525,764 shares against out of ~1.66M voted), advisory vote on executive compensation (611,957 against), and transacting other business (666,212 against). All items ultimately passed despite the mixed support.

• ·Item 1 (financial statements and auditor’s report) was duly adopted without specific vote counts provided.
• ·Hopewell received the lowest For votes among directors (1,027,692) and highest withheld (629,290).
• ·Non-votes ranged from 0 to 553,295 across items.

27-02-2026

Flagstar Bank, N.A. (NYSE: FLG) announced its 2026 Annual Meeting of Shareholders on June 9, 2026, at 10:00 a.m. ET in a virtual format, with a record date of April 10, 2026; proxy materials will be filed with the OCC and SEC. As of December 31, 2025, the Bank reported $87.5B in assets, $61.0B in loans, $66.0B in deposits, and $8.1B in stockholders' equity, while operating approximately 340 locations across ten states. The release includes cautionary forward-looking statements referencing prior events like the October 2025 reorganization and no new performance metrics.

• ·Bank headquartered at 102 Duffy Avenue, Hicksville, NY 11801.
• ·Operates with strong footholds in greater New York/New Jersey, upper Midwest, Florida, and West Coast.

27-02-2026

On February 27, 2026, Bridgewater Bancshares, Inc. and its subsidiary Bridgewater Bank entered into an Equity Distribution Agreement with Piper Sandler & Co. to issue and sell up to $50 million of common stock through at-the-market offerings. The agreement allows sales via various methods, with the company paying a 2.5% commission on gross sales prices; there is no obligation to sell any shares, and either party may terminate at any time. Net proceeds, if any, will support general corporate purposes such as subsidiary investments, working capital, capital expenditures, stock repurchases, debt repayment, or acquisitions.

• ·Sales under the agreement will be made pursuant to shelf registration statement Form S-3 (No. 333-284662), effective February 10, 2025, with prospectus supplement filed February 27, 2026.
• ·Agreement includes customary representations, warranties, covenants, indemnification, and expense reimbursements.

27-02-2026

Pulse Biosciences, Inc. announced the immediate resignation of Kevin P. Danahy, its Chief Commercial Officer, effective February 27, 2026. The departure was not due to any disagreement with the company's operations, policies, practices, or accounting matters. The company recognized Mr. Danahy's contributions to senior management and early commercialization efforts.

• ·Resignation effective immediately
• ·No disagreement on operations, policies, practices, or accounting
• ·Company headquartered at 601 Brickell Key Drive, Suite 1080, Miami, Florida 33131